Roth Capital Analysts Decrease Earnings Estimates for ZVRA

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at Roth Capital decreased their FY2024 earnings estimates for shares of Zevra Therapeutics in a research note issued to investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($1.95) per share for the year, down from their prior forecast of ($1.57). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.38) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.31) EPS, FY2026 earnings at $0.67 EPS, FY2027 earnings at $1.41 EPS and FY2028 earnings at $1.85 EPS.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday. JMP Securities assumed coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 target price on the stock. Roth Mkm lifted their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Maxim Group upped their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Monday, September 30th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Down 4.5 %

Shares of ZVRA opened at $8.62 on Friday. The firm’s 50 day moving average is $8.03 and its 200-day moving average is $6.50. Zevra Therapeutics has a 12 month low of $4.18 and a 12 month high of $9.21. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. The stock has a market capitalization of $453.57 million, a PE ratio of -4.38 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period last year, the firm earned ($0.40) earnings per share.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently made changes to their positions in the stock. FMR LLC increased its holdings in Zevra Therapeutics by 282,687.5% during the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after acquiring an additional 2,312,384 shares during the period. Vanguard Group Inc. raised its position in shares of Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after buying an additional 58,866 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after buying an additional 129,600 shares in the last quarter. State Street Corp boosted its stake in Zevra Therapeutics by 7.4% during the third quarter. State Street Corp now owns 772,825 shares of the company’s stock valued at $5,363,000 after buying an additional 52,966 shares during the period. Finally, Stonepine Capital Management LLC purchased a new position in Zevra Therapeutics during the third quarter worth about $4,858,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.